RA Capital Boosts Artiva Biotherapeutics Stake to 33.7% with $100M Offering Investment
ARTV has more than doubled off its 52-week low of $1.47.
Summary
RA Capital Management, a major institutional investor, significantly increased its stake in Artiva Biotherapeutics by purchasing nearly $100 million in common stock and pre-funded warrants as part of the company's recent public offering, raising its beneficial ownership to 33.7%.
Key Events · Ownership and Investor Activity · ARTV
-
Major Institutional Investment
RA Capital Management, L.P. purchased approximately $100 million in common stock and pre-funded warrants on May 11, 2026.
-
Increased Ownership Stake
This transaction increases RA Capital's beneficial ownership to 33.7% of Artiva Biotherapeutics' common stock.
-
Participation in Public Offering
The purchase was made as part of the company's recent public offering, demonstrating strong institutional support following positive clinical data.
Analysis · ARTV · Life Sciences
This Schedule 13D/A confirms a substantial $100 million investment by RA Capital Management, a major institutional investor, into Artiva Biotherapeutics' recent public offering. This significant capital injection, which increases RA Capital's beneficial ownership to 33.7%, follows the company's positive initial clinical data for its lead program, AlloNK, and provides strong validation of its prospects. The investment represents a critical vote of confidence from a key stakeholder, especially after the company's recent capital raise.
At the time of this filing, ARTV was trading at $10.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $259.5M. The 52-week trading range was $1.47 to $14.53. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.